FAROZYN
DEAD

Serial Number

87648357

Owner

Teva Pharmaceuticals USA, Inc.

Filing Date

Oct 17, 2017

Add to watchlist:

No watchlists yet
View on USPTO

FAROZYN Trademark

Serial Number: 87648357

FAROZYN is a trademark filed by Teva Pharmaceuticals USA, Inc. on October 17, 2017. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Teva Pharmaceuticals USA, Inc. (585 trademarks)

650 Cathill Road
Sellersville, PA 18960

Entity Type: 03

Trademark Details

Filing Date

October 17, 2017

Registration Date

Not Registered

Published for Opposition

January 2, 2018

Goods & Services

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system

Filing History

ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Oct 1, 2018 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Oct 1, 2018 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 27, 2018 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 2, 2018 NPUB
PUBLISHED FOR OPPOSITION
Jan 2, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 13, 2017 NONP
ASSIGNED TO LIE
Nov 26, 2017 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 9, 2017 CNSA
EXAMINER'S AMENDMENT ENTERED
Nov 9, 2017 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 9, 2017 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 9, 2017 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 9, 2017 CNEA
ASSIGNED TO EXAMINER
Nov 3, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 26, 2017 NWOS
NEW APPLICATION ENTERED
Oct 20, 2017 NWAP